Seragon Biosciences has launched Enlivien®, a novel sleep and longevity optimizer designed to address the cellular consequences of insufficient sleep, according to the company. The formulation combines proprietary anti-oxidative and anti-inflammatory compounds with mitochondrial-supporting molecules, the company said.
The company highlights that chronic sleep deprivation, which affects tens of millions in the U.S., not only impairs cognitive performance and work productivity but also accelerates aging and raises risks for disorders including cardiovascular, neurodegenerative and immune conditions as well as cancer.
The scientific basis for Enlivien stems from preclinical research led by a neurobiology associate professor at Harvard Medical School, which found that neutralizing reactive oxygen species (ROS) in the gut of animal models extended lifespan despite ongoing sleep loss. Based on these findings, the company claims that Enlivien’s mechanism of action targets oxidative damage, supports mitochondrial function, and preserves redox balance—particularly in the gut, where molecular disruption from sleep deprivation can trigger nutrient absorption issues, immune dysfunction and increased mortality risk.
Seragon said the formulation leverages advanced ingredient delivery technologies aimed at improving bioavailability and efficacy, to maximize its potential benefits.
